

Clovis Oncology, Inc.  
Form 8-K  
January 25, 2016

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d)**  
**of the Securities Exchange Act of 1934**

**Date of Report (Date of Earliest Event Reported): January 25, 2016**

**Clovis Oncology, Inc.**

**(Exact name of registrant as specified in its charter)**

**Delaware**  
**(State or other jurisdiction**

**of incorporation)**

**5500 Flatiron Parkway, Suite 100**

**001-35347**  
**(Commission**

**File Number)**

**90-0475355**  
**(I.R.S. Employer**

**Identification No.)**

**80301**

**Boulder, Colorado**

**(Address of principal executive offices)**

**(Zip Code)**

**Registrant's telephone number, including area code: (303) 625-5000**

**Not Applicable**

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

(b) Retirement of Named Executive Officer

On January 25, 2016, Clovis Oncology, Inc. (the Company ) announced that Steven L. Hoerter has notified the Company that he resigned from his position as Chief Commercial Officer of the Company. The Company also announced that Dale Hooks, the Company's current Vice President of Sales, has been promoted to Senior Vice President and Chief Commercial Officer of the Company effective as of February 1, 2016.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**CLOVIS ONCOLOGY, INC.**

January 25, 2016

By: /s/ Erle T. Mast

Name: Erle T. Mast

Executive Vice President and Chief Financial

Title: Officer